💊 **Sun Pharma’s ILUMYA® Achieves Positive Phase 3 Results for Psoriatic Arthritis**

Mumbai, 21st July 2025** — Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA) has announced that its Phase 3 clinical studies for **Tildrakizumab 100mg (marketed as ILUMYA®)** in **active psoriatic arthritis (PsA)** have successfully met their **primary endpoints**. These positive results mark a significant milestone in Sun Pharma’s ambition to expand ILUMYA’s indications beyond moderate-to-severe plaque psoriasis. The **INSPIRE-1 and INSPIRE-2 global Phase 3 trials** demonstrated **statistically significant improvements (ACR20 responses)** at **week 24** versus placebo, confirming ILUMYA’s efficacy in reducing symptoms of active psoriatic arthritis. These results strengthen the case for potential regulatory submissions in the United States and other key markets. **Safety data** remained consistent with ILUMYA’s known profile, with no new safety concerns identified. These findings reaffirm ILUMYA’s promise in autoimmune inflammatory treatments. ### 🔍 **Strategic Implications** This development expands Sun Pharma’s specialty pipeline, reinforcing its growing position in **immunology and rheumatology segments**. If approved for psoriatic arthritis, ILUMYA could unlock a sizable growth opportunity alongside its existing psoriasis franchise, further diversifying Sun’s specialty revenues. With these results, Sun Pharma positions itself more strongly in competing with established global biologics players in the autoimmune space. ### **Disclaimer:** This article is for informational purposes only and does not constitute investment advice.